An orally disintegrating medication used to prevent nausea and vomiting by selectively blocking 5-HT3 receptors in the central nervous system and gastrointestinal tract.

Indications:
- Prevention of chemotherapy-induced nausea and vomiting (high or moderate emetogenic risk).
- Prevention of radiotherapy-induced nausea and vomiting.
- Prevention of postoperative nausea and vomiting.

Main Active Ingredient:
- Ondansetron 8 mg.

Precautions:
- Avoid in patients with hypersensitivity to ondansetron or any component of the formulation.
- Use with caution in patients with congenital long QT syndrome or electrolyte abnormalities.
- Monitor for signs of serotonin syndrome when used with other serotonergic drugs.
- Monitor for myocardial ischemia after oral administration.
- Avoid masking of progressive ileus or gastric distension following abdominal surgery or chemotherapy.
- Contains phenylalanine; inform patients with phenylketonuria.

Side Effects:
- Headache, malaise, fatigue, constipation, diarrhea.
- Hypoxia (in postoperative use).
- Rare hypersensitivity reactions, including anaphylaxis and bronchospasm.

Drug-Drug Interactions:
- Avoid concurrent use with apomorphine (used in Parkinson’s disease).
- Use with caution with serotonergic medications such as fluoxetine, paroxetine, sertraline, citalopram, escitalopram, venlafaxine, and duloxetine.
- Use with caution with drugs that prolong the QT interval, such as amiodarone, sotalol, quinidine, procainamide, erythromycin, clarithromycin, haloperidol, ziprasidone, and methadone.